Sugar-free antibodies--the bacterial solution to autoimmunity?
Allhorn, Maria LU and Collin, Mattias LU
(2009)
6th International Congress on Autoimmunity
In Annals of the New York Academy of Sciences
1173.
p.664-669
- Abstract
- The enzyme EndoS from Streptococcus pyogenes is an immunomodulatory molecule hydrolyzing the conserved glycans in the effector part of immunoglobulin G (IgG). EndoS is remarkably specific for IgG, and hydrolysis has profound effects on IgG effector functions. EndoS pretreatment of IgG, or direct administration to animals with experimental antibody-mediated autoimmune diseases, inhibits development of disease or cures animals from established disease. The properties of EndoS make it a unique experimental tool and an attractive alternative to current therapies of conditions involving pathogenic antibodies. This review describes the discovery of EndoS, the effects of EndoS on IgG effector functions in vitro and in vivo, the biotechnological... (More)
- The enzyme EndoS from Streptococcus pyogenes is an immunomodulatory molecule hydrolyzing the conserved glycans in the effector part of immunoglobulin G (IgG). EndoS is remarkably specific for IgG, and hydrolysis has profound effects on IgG effector functions. EndoS pretreatment of IgG, or direct administration to animals with experimental antibody-mediated autoimmune diseases, inhibits development of disease or cures animals from established disease. The properties of EndoS make it a unique experimental tool and an attractive alternative to current therapies of conditions involving pathogenic antibodies. This review describes the discovery of EndoS, the effects of EndoS on IgG effector functions in vitro and in vivo, the biotechnological potential of EndoS, and the outcomes of EndoS treatment in animal models of autoimmunity. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1507048
- author
- Allhorn, Maria
LU
and Collin, Mattias
LU
- organization
- publishing date
- 2009
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Streptococcus pyogenes, autoantibodies, autoimmunity, glycosylation, endoglycosidase, immunoglobulin, glycan hydrolysis
- in
- Annals of the New York Academy of Sciences
- volume
- 1173
- pages
- 664 - 669
- publisher
- Wiley-Blackwell
- conference name
- 6th International Congress on Autoimmunity
- conference location
- Oporto, Portugal
- conference dates
- 2008-09-10 - 2008-09-14
- external identifiers
-
- wos:000270762800091
- pmid:19758213
- scopus:69949159693
- pmid:19758213
- ISSN
- 0077-8923
- DOI
- 10.1111/j.1749-6632.2009.04739.x
- language
- English
- LU publication?
- yes
- id
- 54075926-816b-496d-bb57-11500980994c (old id 1507048)
- date added to LUP
- 2016-04-01 13:26:56
- date last changed
- 2022-02-06 21:16:53
@article{54075926-816b-496d-bb57-11500980994c,
abstract = {{The enzyme EndoS from Streptococcus pyogenes is an immunomodulatory molecule hydrolyzing the conserved glycans in the effector part of immunoglobulin G (IgG). EndoS is remarkably specific for IgG, and hydrolysis has profound effects on IgG effector functions. EndoS pretreatment of IgG, or direct administration to animals with experimental antibody-mediated autoimmune diseases, inhibits development of disease or cures animals from established disease. The properties of EndoS make it a unique experimental tool and an attractive alternative to current therapies of conditions involving pathogenic antibodies. This review describes the discovery of EndoS, the effects of EndoS on IgG effector functions in vitro and in vivo, the biotechnological potential of EndoS, and the outcomes of EndoS treatment in animal models of autoimmunity.}},
author = {{Allhorn, Maria and Collin, Mattias}},
issn = {{0077-8923}},
keywords = {{Streptococcus pyogenes; autoantibodies; autoimmunity; glycosylation; endoglycosidase; immunoglobulin; glycan hydrolysis}},
language = {{eng}},
pages = {{664--669}},
publisher = {{Wiley-Blackwell}},
series = {{Annals of the New York Academy of Sciences}},
title = {{Sugar-free antibodies--the bacterial solution to autoimmunity?}},
url = {{http://dx.doi.org/10.1111/j.1749-6632.2009.04739.x}},
doi = {{10.1111/j.1749-6632.2009.04739.x}},
volume = {{1173}},
year = {{2009}},
}